LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
13 Novembre 2023 - 2:30PM
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”)
(Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company
developing a new class of cancer therapy to enhance chemotherapy
and immunotherapy benefit, today provided an update on its
progress.
Clinical Trial and Other
Advancements
Year-to-date, LIXTE has made advances in the
development of LB-100 through important collaborations, including
the following:
- Collaboration
with GSK and The University of Texas - MD Anderson Cancer Center in
an investigator-initiated Phase 1b/2 clinical trial assessing
whether adding LB-100 to GSK’s programmed death receptor-1
(PD-1)-blocking monoclonal antibody may enhance the effectiveness
of immunotherapy in the treatment of ovarian clear cell carcinoma.
GSK will provide dostarlimab and financial support for the clinical
trial. In addition to MD Anderson, the trial also will be open at
Northwestern University’s Robert H. Lurie Comprehensive Cancer
Center.
- The first
patient was enrolled in the Spanish Sarcoma Group (Grupo Español de
Investigación en Sarcomas – GEIS) trial to determine whether LB-100
given with a standard dose of doxorubicin for the treatment of
advanced soft tissue sarcomas (ASTS) will improve progression-free
survival and overall survival. This trial will enroll up to 170
patients and will begin in partnership with GEIS clinical
sites.
- Sarah Cannon Research Institute
(SCRI) joined the City of Hope’s ongoing Phase 1b clinical trial
evaluating the addition of LB-100 to chemotherapy and immunotherapy
for previously untreated, extensive-stage small cell lung cancer.
Adding SCRI is expected to reduce the time required to demonstrate
the feasibility, tolerability and efficacy of adding LB-100 to the
current standard of care.
- Expanded collaboration with the
Netherlands Cancer Institute (NKI) and Oncode Institute to
study pre-clinical drug synergies of LB-100 with chemotherapy and
immunotherapy in various cancers. The expansion follows a
successful two-year collaboration in colon cancer and seeks to
discover additional treatment combinations with LB-100 for other
cancer types. A recently posted article in BioRxiv detailed that
the collaboration demonstrated that inhibition of PP2A in colon
cancer cells by LB-100 may lead to an improvement in immunotherapy
response.
Bas van der Baan, LIXTE’s recently-appointed
President and Chief Executive Officer, said, “Since the beginning
of this year, LIXTE has been expanding its collaborations with
several prestigious, world-renowned cancer research institutions
and pharmaceutical companies that are testing our LB-100 compound
to improve chemotherapy and immunotherapy treatment outcomes. We
believe that LB-100 may offer broad applicability to many types and
stages of cancer, with the potential to benefit a wide range of
patients.”
Other Corporate News
- Bas van der
Baan, 51, was named President and Chief Executive Officer of LIXTE
in September 2023. He was subsequently named Chairman of the Board
of Directors as a result of the passing of LIXTE’s founder, Dr.
John S. Kovach, on October 5, 2023. He had previously joined
LIXTE’s Board of Directors in June 2022. With more than two decades
of experience in the biotechnology industry, focused on oncology
and diagnostics, Mr. van der Baan will lead the Company as it works
toward its mission of improving medical outcomes for patients
undergoing various chemotherapies and immunotherapies for cancer,
while establishing and commercializing LB-100.
- The Company closed a registered
direct offering with an institutional investor for 583,334 shares
of common stock (including pre-funded warrants) and a concurrent
private placement of common warrants to purchase up to 583,334
shares of common stock at a purchase price of $6.00 per common
share in July 2023. The gross proceeds from the offering were
approximately $3,500,000, with net proceeds of approximately
$3,137,000.
Filing of September 30, 2023 Quarterly Report on Form
10-Q
Additional information with respect to LIXTE’s
business, clinical trials and financial condition is contained in
the Company’s Quarterly Report on Form 10-Q for the quarterly
period ended September 30, 2023, which has been filed with the U.S.
Securities and Exchange Commission at www.sec.gov.
About LIXTE Biotechnology Holdings,
Inc.
LIXTE Biotechnology Holdings, Inc. is a
clinical-stage pharmaceutical company developing a new class of
cancer therapy, PP2A inhibitors. The Company’s novel approach
enhances the efficacy of both chemotherapy and
immunotherapy, potentially providing new treatment options for
patients. At the core of the Company’s therapy is LB-100,
LIXTE’s proprietary molecule that acts as an inhibitor of the PP2A
phosphatase with a favorable toxicity profile. LB-100 promotes
the production of neoantigens and cytokines, boosts T-cell
proliferation, and disrupts the DNA repair mechanisms of cancer
cells, potentially improving treatment outcomes. The Company is
conducting multiple clinical trials for solid tumors with unmet
medical needs. LIXTE's unique approach has no known
competitors and is covered by a comprehensive patent
portfolio.
Additional information about LIXTE can be found
at www.lixte.com, on LinkedIn at
https://www.linkedin.com/company/lixte-biotechnology-holdings-inc-/,
on Twitter at https://twitter.com/LixteBiotech, and by reviewing
the Company's filings with the United States Securities and
Exchange Commission at https://www.sec.gov.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
clinical trials and collaborators in such clinical trials, business
strategy and other plans and objectives for future operations, and
assumptions and predictions about future activities, including the
continuing development of proprietary compounds, the planning,
funding, coordination and potential results of clinical trials, and
the patent and legal costs to protect and maintain the Company's
intellectual property worldwide, are all forward-looking
statements. These statements are generally accompanied by
words such as "intend," anticipate," "believe," "estimate,"
"potential(ly)," "continue," "forecast," "predict," "plan," "may,"
"will," "could," "would," "should," "expect" or the negative of
such terms or other comparable terminology. The Company
believes that the assumptions and expectations reflected in such
forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide
assurances that these assumptions and expectations will prove to
have been correct or that the Company will take any action that the
Company may presently be planning. However, these
forward-looking statements are inherently subject to known and
unknown risks and uncertainties. Actual results or experience
may differ materially from those expected or anticipated in the
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, regulatory
policies, available cash, research results, competition from other
similar businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
www.sec.gov.
For more information about
LIXTE, Contact:info@lixte.comGeneral Phone: (631)
830-7092Investor Phone: (888) 289-5533orPondelWilkinson Inc.
Investor Relations pwinvestor@pondel.comRoger Pondel or Laurie
Berman: (310) 279-5980
# # #
Lixte Biotechnology (NASDAQ:LIXT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Lixte Biotechnology (NASDAQ:LIXT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024